We didn't know the AVXL data; we know what CYDY is presenting: Pro 140 works as a monotherapy. Not much new besides the PK/PD data which doesn't make a big difference because Pro 140 has touted that Pro 140 works so the PK/PD HAS to be good. The hype behind the ASM is for publicity. CYDY thinks this is their chance to get their name out there and get some attention. Let's hope that's the fact.
Data was good and actually AVXL was climbing after the uplist to the NASDAQ. The problem with AVXL wasn't the data its that Adam F wrote a damaging article which caused a mass panic sell by investors. It went from being $10 per share to where it is now because of the negative article. If he writes a negative article on the biotech stock (adam F.) his cronies help short the stock at the same time making good coin. That's why AVXL dipped. If not for that negative article I think AVXL would be trading higher.
Market Data 
Markets 
AI
